We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Cardiology

Evaluating the Heart Failure Risk in Type 2 Diabetes: Insights from 1.6 Million People in England

MedXY Editorial Team•Oct 2, 2025•Cardiology
epidemiologyheart failuretype 2 diabetes

Type 2 diabetes mellitus (T2DM) is a growing global health concern, significantly increasing the risk of cardiovascular diseases, particularly heart failure. Heart failure can be classified into ischaemic and non-ischaemic forms, with the former typically linked to coronary artery disease and myocardial infarction, while the latter encompasses various other mechanisms, including diastolic dysfunction and hypertensive heart disease.

Recent epidemiological data suggest a declining trend in ischaemic heart disease (IHD) rates across numerous populations, potentially influencing heart failure presentations. Given the changing landscape of cardiovascular morbidity, it becomes critical to understand whether these trends also extend to heart failure phenotypes among individuals with diabetes.

This study investigates the relative risks of ischaemic and non-ischaemic heart failure in individuals diagnosed with T2DM, providing crucial data that could inform preventive healthcare strategies and resource allocation for this population.

Study Design

This observational study utilised the Clinical Practice Research Datalink (CPRD), which integrates primary care data with hospital admissions and mortality records. Participants included newly diagnosed adults with T2DM from January 2000 to December 2021. Each diabetic individual was matched with up to four non-diabetic individuals based on sex, birth year, and general practice.

Definitions were as follows: ischaemic heart failure was characterised as new heart failure diagnosed after or during an ischaemic heart disease event. Conversely, non-ischaemic heart failure referred to newly diagnosed heart failure without a preceding ischaemic event.

The incidence rates of heart failure types and hazard ratios were calculated using Poisson and Royston-Parmar models, with adjustments for various sociodemographic and clinical confounders.

Key Findings

A total of 1,621,090 individuals were included in the analysis, with a mean follow-up period of 5.8 years (interquartile range 2.6–10.3). Among the included subjects, 532,185 had a diagnosis of T2DM. The incidence of heart failure was significantly higher in the diabetic group, with 20,016 cases (3.8%); breakdown indicated 5,046 waschaemic heart failure and 14,970 non-ischaemic heart failure. Comparatively, the non-diabetic cohort exhibited 29,835 heart failure cases (2.7%).

Crucially, age-standardised incidence rates revealed non-ischaemic heart failure events occurring at a rate of 3.18 (95% CI: 3.09-3.27) per 1000 person-years for men with diabetes versus 2.08 (95% CI: 2.03-2.12) for men without diabetes. For women, the rates were 2.47 (95% CI: 2.39-2.54) compared to 1.57 (95% CI: 1.53-1.61). In terms of ischaemic heart failure, incidence rates were 1.57 (95% CI: 1.51-1.63) versus 0.95 (95% CI: 0.92-0.98) for men and 0.80 (95% CI: 0.76-0.84) versus 0.46 (95% CI: 0.44-0.48) for women.

Adjusted hazard ratios indicated that individuals with T2DM had a greater risk for both heart failure types. For ischaemic heart failure, hazard ratios were 1.36 (95% CI: 1.28-1.45) for men and 1.30 (95% CI: 1.20-1.42) for women. Non-ischaemic heart failure risks were lower at 1.12 (95% CI: 1.07-1.16) for men and 1.10 (95% CI: 1.06-1.14) for women, showing the relatively lower but still increased risk among diabetic patients.

These findings affirm the hypothesis that while diabetes increases the risk of heart failure in general, those affected by diabetes are more likely to develop non-ischaemic forms.

Expert Commentary

The given data highlights essential implications for clinical management and preventive strategies regarding heart failure among those with T2DM. The significant risk posed by non-ischaemic heart failure in the diabetic population should urge clinicians to consider comprehensive heart health monitoring and interventions focusing on lifestyle modifications and early screening practices tailored to diabetes.

While the study relies heavily on observational data, thus limiting causal conclusions, the robustness of the CPRD dataset warrants confidence in the observed associations. It’s essential to note that there exist potential biases related to diagnostic practices or recording completeness in primary care settings. Future studies could explore a more granular classification of non-ischaemic heart failures, alongside in-depth investigations into the underlying pathophysiological mechanisms.

Conclusion

The escalating rates of non-ischaemic heart failure among individuals with T2DM underscore a substantial unmet need for early intervention strategies aimed at preventing both heart failure forms. Clinicians must recognize the elevated risk for ischaemic heart failure, as it appears that post-event preventive measures may not be sufficiently robust amongst this demographic.

Future directives should emphasize enhancing awareness, preventive measures, and research into optimizing treatment frameworks that address both heart failure types in diabetic patients, thereby improving clinical outcomes and quality of life.

Reference

Panchal K, Lawson C, Shabnam S, Khunti K, Zaccardi F. Risk of Ischaemic and Non-Ischaemic Heart Failure in People With Type 2 Diabetes: Observational Study in 1.6 Million People in England. Diabetes Metab Res Rev. 2025 Sep;41(6):e70072. doi: 10.1002/dmrr.70072IF: 6.0 Q1 . PMID: 40722166; PMCID: PMC12304495.

  • PDF (432.4 KB)

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Fenofibrate Use and Reduced Risk of Sight-Threatening Diabetic Retinopathy in Type 2 Diabetes: Insights from UK Real-World DataFenofibrate use in type 2 diabetes patients is associated with a significant reduction in the risk of sight-threatening diabetic retinopathy compared to statins, based on UK primary care data over 12 years.Sep 18, 2026Bridging Evidence-Based and Personalized Medicine in Heart Failure and Cardiomyopathies: Balancing Standardization with IndividualizationThis article explores the integration of evidence-based medicine and personalized approaches in managing heart failure and inherited cardiomyopathies, proposing a framework to optimize patient care by harmonizing standardized guidelines witSep 17, 2026Global Burden of Disorders of Gut-Brain Interaction: Insights from Rome V Versus Rome IV CriteriaThe Rome V global epidemiology survey confirms a high prevalence of disorders of gut-brain interaction (DGBI) worldwide, consistent with prior Rome IV findings, underscoring a significant and persistent global clinical burden.Sep 15, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Differential Gastrointestinal Risks of Opioids in Type 2 Diabetes Patients on GLP-1RA Therapy: A Comparative Analysis
Among type 2 diabetes patients using GLP-1 receptor agonists, oxycodone is linked to higher short-term risks of severe gastrointestinal complications compared to hydrocodone and tramadol, warranting cautious opioid selection in this populat
Sep 15, 2026
Cardiac Resynchronization Therapy: Metabolomic Insights into Heart Failure ImprovementThis study reveals how cardiac resynchronization therapy (CRT) improves left ventricular function in heart failure patients and modulates systemic metabolomic profiles, highlighting differences between ischemic and nonischemic cardiomyopathSep 15, 2026
Common Anti-Inflammatory Drugs Linked to Lower Risk of Vision-Threatening Diabetic Retinopathy in Type 2 DiabetesA large retrospective cohort study suggests that cetirizine, ibuprofen, and prednisone use in adults with type 2 diabetes is associated with significantly reduced incidence of diabetic macular edema and proliferative diabetic retinopathy, hSep 15, 2026